The Federal Trade Commission requested Friday that a federal judge hold “Pharma Bro” Martin Shkreli in civil contempt for failing to abide by the stipulations of a Feb. 4, 2022 court order.
That order from the U.S. District Court for the Southern District of New York (USDC-SDNY) banned Shkreli from participation in the pharmaceutical industry for life, and enjoined him to pay $64.6 million. Shkreli, who was imprisoned on a seven-year sentence for defrauding investors at the time of the order, was released early in May.
Plaintiffs, including the Federal Trade Commission and seven states, also have the right to ask for compliance reporting and interviews to ensure Shkreli abides by the order.